Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study

Abstract: 5131
Congress: ESMO 2010
Type: Abstract
Topic: Breast cancer, advanced
Authors: C. Twelves1, C. Akerele2, J. Wanders3, J.A. Cortes4; 1Leeds/GB, 2Woodcliff Lake, NJ/US, 3Hatfield/GB, 4Barcelona/ES